Diffusion Pharmaceuticals To Present At Cavendish Global Health Impact Forum
NEW YORK, Oct. 30, 2014 /PRNewswire-USNewswire/ -- Cavendish Global announced today the selection of Diffusion Pharmaceuticals LLC, a company developing new drugs for the treatment of cancer and other life-threatening medical conditions, to present at the Cavendish Global Health Impact Forum taking place Monday, November 10th to Thursday, November 13th at Oxford University in the United Kingdom. The purpose of the by-invitation Forum is to help family offices and foundations develop and implement their individual impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. Diffusion Pharmaceuticals presented in May of this year at the Cavendish Global Health Impact Forum that was hosted at the United Nations Headquarters and The Rockefeller University in New York. Michael Moffat, Cavendish co-founder and President said, "Our members were intrigued by the mission and accomplishments of Diffusion Pharmaceuticals at the New York Forum. We are glad they now have the opportunity to share their important story this November at our Oxford University hosted Forum. The quality and originality of Diffusion Pharma's research and scientific insights in the improved treatment of cancer positions them to make a major contribution to the current standard of care."
"We are honored to be continuing our partnership with this unique community," said Diffusion's CEO, David Kalergis. "Our work was well received at the Cavendish Forum in New York and we look forward to telling our story once again at Oxford University. Our inclusion in the Cavendish community is further recognition of our innovative approach to the treatment of brain cancer afflicting populations around the world today. We particularly welcome the chance to meet with many of world's leading scientific minds, thought-leaders and generous individuals and families all of whom are dedicated to the common cause of improving the health of people around the world."
Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences. The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing. The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.
About Cavendish Global
Cavendish Global provides leading family offices and their foundations from around the world with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual impact investment, grant-giving and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative advisory and digital resources, which includes Cavendish Impact Forums. A unique gathering of leading family offices, Cavendish Forums take place three times each year and are hosted by leading institutions around the world. In May of 2014 the Cavendish Global Health Impact Forum was hosted at the United Nations Headquarters, Secretariat Building New York, The Rockefeller University and The New York Academy of Sciences. Following the Oxford University hosted Cavendish Forum in November of this year, the Cavendish community of family offices will next convene in the spring of 2015 in the United States.
For more information: http://cavendishglobal.com
President, Strategic Alliances, Cavendish Global
Direct Line: +1-917-576-1435
About Diffusion Pharmaceuticals LLC
Diffusion Pharmaceuticals is a Charlottesville, Virginia, USA, based biotechnology company developing new drugs which help regulate the movement of oxygen into tissue by a novel mechanism of action. Because oxygen is fundamental to life's processes, these drugs offer promising new treatments for a host of life-threatening diseases, including cancer, stroke, and heart attack. Diffusion's lead drug, trans sodium crocetinate (TSC), uses this mechanism to sensitize cancerous cells to the tumor killing power of standard radiation therapy. The Company is now completing a clinical trial testing the safety and efficacy of TSC in newly-diagnosed primary brain cancer (glioblastoma multiforme) patients.
For Further Information Contact:
David G. Kalergis, JD/MBA
CEO, Diffusion Pharmaceuticals LLC
2020 Avon Court, # 4
Charlottesville, Virginia 22902
Phone: 434 220-0718
Fax: 434 220-0722
SOURCE Cavendish Global